(Q34483473)

2 August 2017

A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors (English)

1 reference

2 August 2017

phase I clinical trial

0 references

0 references

1 reference

4

E Claire Dees

1 reference

2 August 2017

Hatem H Soliman

1

1 reference

2 August 2017

Erica Jackson

2

1 reference

2 August 2017

Tony Neuger

3

1 reference

2 August 2017

R Donald Harvey

5

1 reference

2 August 2017

Hyo Han

6

1 reference

2 August 2017

Roohi Ismail-Khan

7

1 reference

2 August 2017

Susan Minton

8

1 reference

2 August 2017

Nicholas N Vahanian

9

1 reference

2 August 2017

Charles Link

10

1 reference

2 August 2017

Daniel M Sullivan

11

1 reference

2 August 2017

Scott Antonia

12

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 September 2014

1 reference

2 August 2017

1 reference

2 August 2017

5

1 reference

2 August 2017

8136-8146

1 reference

2 August 2017

18

1 reference

The interplay between the immune system and chemotherapy: emerging methods for optimizing therapy

2 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226672

Checkpoint modulation in melanoma: an update on ipilimumab and future directions

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226672

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226672

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226672

IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226672

Blocking IDO activity to enhance anti-tumor immunity.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226672

T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226672

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226672

Hallmarks of Cancer: The Next Generation

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226672

The anticancer immune response: indispensable for therapeutic success?

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226672

Creating immune privilege: active local suppression that benefits friends, but protects foes.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226672

Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226672

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226672

Tolerance, DCs and tryptophan: much ado about IDO

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226672

Enhancement of tumor radioresponse by docetaxel: Involvement of immune system.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226672

Inhibition of T cell proliferation by macrophage tryptophan catabolism

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226672

Prevention of allogeneic fetal rejection by tryptophan catabolism

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226672

Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226672

Phase II multicenter study of docetaxel and bevacizumab with or without trastuzumab as first-line treatment for patients with metastatic breast cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226672

Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226672

Phase III Trial Comparing Three Doses of Docetaxel for Second-Line Treatment of Advanced Breast Cancer

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226672

Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--response

9 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25327557

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Docetaxel: standard recommended dose of 100 mg/m(2) is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy-A phase II single-center study

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25327557

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25327557

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.18632/ONCOTARGET.2357

0 references

PMCID

4226672

1 reference

2 August 2017

1 reference